Back to today’s briefing

Story perspectives

PureTech Transfers Lead Drug to Celea for Innovation Boost

8/14/2025

36 8

Summary

Story summary

PureTech Health is making a bold move by transferring its lead drug to Celea Therapeutics, a decision that reflects its commitment to innovation in the biotech industry. This strategic shift is designed to accelerate the drug's development and commercialization, promising a brighter future for patients in need.

1 of 1

Story summary

PureTech Health is making a bold move by transferring its lead drug to Celea Therapeutics, a decision that reflects its commitment to innovation in the biotech industry. This strategic shift is designed to accelerate the drug's development and commercialization, promising a brighter future for patients in need.